Hormonal suppression for fertility preservation in males and females.
Methods to restore fertility of men and women sterilized by medical treatments and environmental toxicant exposures are under investigation. Rendering spermatogenesis and ovarian follicular development kinetically quiescent by suppression of gonadotropins has been proposed to protect them from damage by cytotoxic therapy. Although the method fails to protect the fertility of male mice and monkeys, gonadotropin and testosterone suppression in rats before or after cytotoxic therapy do enhance the recovery of spermatogenesis. However, the mechanism involves not the induction of quiescence but rather the reversal, by suppression of testosterone, of a block in differentiation of surviving spermatogonia caused by damage to the somatic environment. In men, only one of eight clinical trials was successful in protecting or restoring spermatogenesis after cytotoxic therapy. In women, protection of primordial follicles in several species from damage by cytotoxic agents using GnRH analogs has been claimed; however, only two studies in mice appear convincing. The protection cannot involve the induction of quiescence in the already dormant primordial follicle but may involve direct effects of GnRH analogs or indirect effects of gonadotropin suppression on the whole ovary. Although numerous studies in female patients undergoing chemotherapy indicate that GnRH analogs might be protective of ovarian function, none of the studies showing protection were prospective randomized clinical trials and thus they are inconclusive. Considering interspecies differences and similarities in the gonadal sensitivity to cytotoxic agents and hormones, mechanistic studies are needed to identify the specific beneficial effects of hormonal suppression in select animal models that may be applicable to humans.
Meistrich
Marvin L
ML
Department of Experimental Radiation Oncology, MD Anderson Cancer Center, The University of Texas, Houston, Texas 77030, USA.
Shetty
Gunapala
G
D000818:Animals; D002986:Clinical Trials as Topic; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists / Q000627:therapeutic use; D006065:Gonadotropins, Pituitary / Q000037:antagonists & inhibitors*; D006801:Humans; D007247:Infertility, Female / Q000209:etiology / Q000517:prevention & control*; D007248:Infertility, Male / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D023421:Models, Animal; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D006080:Ovarian Follicle; D010053:Ovary; D013094:Spermatozoa; D013739:Testosterone / Q000037:antagonists & inhibitors
D006065:Gonadotropins, Pituitary; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone